CD19 and synovial sarcoma: In addition, SS patients had a significant decrease in median value of LDH (p = 0.005), Sézary cells (p = 0.003), CD3 (p = 0.006), CD4 (p = 0.003), CD19 (p = 0.05), sIL‐2R (p = 0.015), and sCD30 (p = 0.04) biomarkers between baseline and follow‐up, whereas those who had eMF had no significant change between baseline and follow‐up (p > 0.05).